Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target Raised to $46.00

Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price objective boosted by Sanford C. Bernstein from $35.00 to $46.00 in a report issued on Wednesday morning,Benzinga reports. Sanford C. Bernstein currently has a market perform rating on the biotechnology company’s stock.

Several other research analysts also recently commented on the company. Royal Bank Of Canada lifted their price objective on Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the stock an “outperform” rating in a report on Friday, May 8th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, May 6th. B. Riley Financial lifted their price objective on Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. Morgan Stanley upgraded Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $78.00 to $100.00 in a report on Tuesday, April 21st. Finally, Piper Sandler reiterated an “overweight” rating and issued a $110.00 price objective (up from $100.00) on shares of Arrowhead Pharmaceuticals in a report on Tuesday, January 13th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $87.80.

Arrowhead Pharmaceuticals Trading Down 3.8%

NASDAQ ARWR opened at $76.67 on Wednesday. The stock’s 50-day simple moving average is $65.94 and its two-hundred day simple moving average is $61.85. Arrowhead Pharmaceuticals has a twelve month low of $14.30 and a twelve month high of $82.26. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 1.41. The company has a market capitalization of $10.80 billion, a price-to-earnings ratio of -35.66 and a beta of 1.28.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.17. The business had revenue of $73.74 million for the quarter, compared to the consensus estimate of $73.84 million. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.The company’s revenue for the quarter was down 86.4% on a year-over-year basis. During the same quarter last year, the business posted $2.75 earnings per share. Research analysts forecast that Arrowhead Pharmaceuticals will post -2.94 EPS for the current fiscal year.

Insider Activity at Arrowhead Pharmaceuticals

In related news, CFO Daniel Joseph Apel sold 13,095 shares of the business’s stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $71.35, for a total transaction of $934,328.25. Following the transaction, the chief financial officer owned 162,905 shares in the company, valued at $11,623,271.75. The trade was a 7.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James C. Hamilton sold 10,000 shares of the business’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $64.19, for a total value of $641,900.00. Following the transaction, the insider owned 236,958 shares in the company, valued at approximately $15,210,334.02. This represents a 4.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 36,065 shares of company stock worth $2,554,562 in the last 90 days. Company insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Tsfg LLC purchased a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter worth approximately $25,000. iSAM Funds UK Ltd bought a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter worth approximately $29,000. First Horizon Corp bought a new stake in shares of Arrowhead Pharmaceuticals in the 4th quarter worth approximately $32,000. WPG Advisers LLC boosted its position in shares of Arrowhead Pharmaceuticals by 384.8% in the 4th quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 431 shares in the last quarter. Finally, Hantz Financial Services Inc. boosted its position in shares of Arrowhead Pharmaceuticals by 177.1% in the 4th quarter. Hantz Financial Services Inc. now owns 737 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 471 shares in the last quarter. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Key Arrowhead Pharmaceuticals News

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright kept a Buy rating and $100 price target on Arrowhead Pharmaceuticals, while also lifting its FY2026 earnings estimate, reinforcing a bullish long-term view on the company’s RNAi pipeline.
• Positive Sentiment: Other recent analyst actions remain constructive, including Royal Bank of Canada raising its price target to $87, JPMorgan starting coverage with an Overweight rating, and Sanford C. Bernstein boosting its target to $46.
• Neutral Sentiment: Arrowhead presented at the Bank of America Global Healthcare Conference, but the headline does not indicate a major new clinical or financial update that would materially change near-term expectations. Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: HC Wainwright made only small mixed tweaks to its 2026-2027 EPS forecasts, suggesting the analyst still sees the bigger story as intact despite minor quarter-to-quarter changes.
• Negative Sentiment: Director Hongbo Lu sold 2,970 shares in a pre-arranged 10b5-1 transaction. The sale was modest relative to his remaining stake, but insider selling can still be viewed cautiously by investors.
• Negative Sentiment: Arrowhead’s latest quarterly results showed a large year-over-year revenue decline and continued losses, reminding investors that the company remains unprofitable and dependent on future pipeline progress.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.